Class IIb Devices: Where Clinical Evaluation Gets Serious

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

Class IIb devices represent a regulatory threshold. Below this line, you can sometimes get away with lighter clinical evidence. Above it, you cannot.

The difference is not just about volume of data. It is about depth of analysis, quality of evidence, and the sophistication of your clinical reasoning. Many manufacturers learn this the hard way during their first Class IIb submission.

Why Class IIb Changes Everything

Under MDR Article 61 and Annex XIV, clinical evaluation requirements intensify significantly for Class IIb devices. This is not about regulatory bureaucracy. It reflects the actual risk these devices carry.

Class IIb devices are invasive, supply energy to the body, or have biological effects that require serious clinical evidence. A surgical instrument that penetrates tissue. A device that delivers therapeutic ultrasound. An implantable sensor.

The clinical evaluation for these devices must demonstrate safety and performance in a way that withstands clinical scrutiny. Not just regulatory compliance—actual clinical credibility.

Most deficiencies I see in Class IIb clinical evaluation reports come from underestimating this threshold. The manufacturer approaches the CER like a Class IIa exercise with more pages. That never works.

The Real Requirements Under MDR

MDR Annex XIV Part A establishes the clinical evaluation framework. For Class IIb devices, several elements become non-negotiable.

First, the State of the Art analysis must be comprehensive. You cannot cherry-pick favorable studies and ignore contradictory evidence. MDCG 2020-6 makes this explicit: your SOTA must reflect what is actually known clinically, not what supports your device.

This means systematic literature searches with documented methodology. Clear inclusion and exclusion criteria. Appraisal of study quality using validated tools. Synthesis of findings that acknowledges gaps and contradictions.

Second, if you claim equivalence, you must demonstrate it rigorously. Technical equivalence is not enough. Clinical equivalence requires proof that the devices behave the same way in the same clinical situations with the same patient populations.

Third, clinical investigations become more likely. For many Class IIb devices, literature and equivalence alone will not suffice. You need device-specific clinical data.

This does not always mean a full clinical trial. But it means you must have data from your device used in real clinical conditions. Registry data, prospective case series, or well-designed observational studies can work—if done properly.

What Notified Bodies Actually Look For

When a Notified Body reviews a Class IIb clinical evaluation, they are looking for clinical thinking, not just documentation.

They want to see that you understand the clinical context. That you know how the device is actually used. That you recognize the relevant clinical risks and have evidence addressing them.

I have watched submissions fail because the clinical evaluation read like a technical manual. Lots of specifications, limited clinical reasoning. The reviewer could not see how the evidence connected to real clinical outcomes.

Here is what makes a difference:

Clinical endpoints that matter. Not just technical performance metrics. Actual patient outcomes, safety events, clinical effectiveness in the intended population.

Appraisal quality. Every study you cite must be evaluated for relevance, reliability, and weight of evidence. MDCG 2020-13 describes the expected approach. Apply it seriously.

Gap analysis. You must identify where evidence is weak or missing and explain how you address those gaps through device design, risk management, PMCF, or clinical investigations.

The other element reviewers focus on is consistency. Your clinical evaluation must align with your risk management file, your IFU, your labeling, and your PMCF plan. Contradictions raise immediate red flags.

The Equivalence Trap for Class IIb

Equivalence is where most Class IIb submissions stumble.

The manufacturer finds a predicate device with clinical data. They compare features, materials, and intended use. They conclude equivalence and incorporate the predicate’s clinical data into their evaluation.

Then the Notified Body asks: how do you know these devices behave the same clinically?

This is not a theoretical question. For Class IIb devices, small technical differences can have significant clinical consequences. A different coating on a catheter. A modified energy delivery pattern in a therapeutic device. A slightly different material composition in an implant.

Each difference must be justified. Why it does not affect clinical outcomes. Why the clinical data from the predicate still applies.

Many manufacturers cannot answer this convincingly because they never tested it. They assumed equivalence based on similarity. That assumption fails under MDR scrutiny.

If you cannot demonstrate equivalence with solid clinical reasoning, you need device-specific data. There is no middle path that satisfies MDR for Class IIb devices.

Clinical Investigation Requirements

MDR Article 61(4) requires clinical investigations for implantable devices and Class III devices, unless you can justify reliance on existing data. For Class IIb, investigations are not always mandatory, but often necessary.

The decision comes down to evidence sufficiency. If literature and equivalence provide sufficient evidence for all claims and all identified risks, you may not need a clinical investigation.

But if gaps exist—and they often do for novel Class IIb devices—you need prospective clinical data.

This does not always mean a randomized controlled trial. Depending on your device and claims, options include:

Prospective single-arm studies demonstrating safety and performance in the intended population.

Registry participation providing real-world evidence over time.

Post-market clinical follow-up designed to generate evidence, not just monitor safety.

The key is designing data collection that actually addresses evidence gaps. Generic PMCF surveys do not count. You need structured data collection with clinical endpoints, defined follow-up, and statistical validity.

PMCF for Class IIb: Beyond Monitoring

For Class IIb devices, PMCF must be proactive. MDR Annex XIV Part B makes this clear. You are not just watching for problems. You are confirming that clinical benefits persist and that residual risks remain acceptable over time.

Your PMCF plan must specify:

Methods for collecting clinical data post-market. Literature surveillance is necessary but not sufficient. You need device-specific data sources.

Clinical endpoints that align with your evaluation. If you claimed reduced infection rates, you must track infection rates post-market.

Analysis triggers. When will you analyze data? What findings would prompt action?

MDCG 2020-7 and MDCG 2020-8 provide detailed guidance on PMCF design. For Class IIb devices, your PMCF plan will be reviewed carefully. Weak plans generate immediate questions from Notified Bodies.

Common Patterns in Rejections

After reviewing dozens of Class IIb submissions, certain deficiency patterns repeat.

Insufficient SOTA. The literature search was too narrow, too old, or excluded relevant clinical areas. The appraisal was superficial.

Weak equivalence justification. Technical comparison without clinical reasoning. Differences dismissed without evidence.

Missing gap analysis. The CER presents available evidence but does not acknowledge where evidence is limited or missing.

Generic PMCF. The plan describes general monitoring but does not target specific evidence gaps or clinical questions.

Inconsistency across files. The CER claims one thing, the risk file says another, the IFU implies something different.

These deficiencies are fixable, but they cost time. The first submission gets rejected. Months pass. The manufacturer revises. If the underlying issue was conceptual—misunderstanding what Class IIb requires—the second submission may fail too.

What You Should Do Differently

If you are preparing a Class IIb clinical evaluation, start by understanding that you are building a clinical argument, not a compliance document.

Ask yourself: if I presented this evaluation to a clinical specialist who uses similar devices, would they find it convincing? Would they trust the evidence? Would they see gaps I am ignoring?

This mindset changes how you approach every section.

Your literature search becomes systematic and transparent. Your appraisal becomes critical, not confirmatory. Your equivalence claim becomes a hypothesis you must prove, not an assumption you assert.

Your PMCF plan becomes a data generation strategy, not a monitoring checklist.

Second, involve clinical expertise early. Not just for review, but for planning. A clinician who understands the device’s use can identify evidence gaps you might miss. They can help define clinically meaningful endpoints. They can assess whether your equivalence claim makes clinical sense.

Third, plan for iterations. Few Class IIb clinical evaluations get approved on the first submission. Expect questions. Build time into your timeline for revisions.

Finally, treat your clinical evaluation as a living document. For Class IIb devices, the initial CER is just the beginning. Post-market data, new literature, field experience—all feed back into updated evaluations.

If your process does not support continuous clinical evaluation, you will struggle with MDR surveillance requirements.

The Bigger Picture

Class IIb marks the line where clinical evaluation becomes genuinely challenging under MDR. It requires clinical thinking, rigorous evidence appraisal, and the honesty to acknowledge what you do not know.

Many manufacturers approach this with a compliance mentality: tell me what documents to produce, and I will produce them. That approach fails because Notified Bodies are not checking boxes. They are assessing clinical credibility.

The devices that pass review are the ones where clinical evaluation was embedded in development from the start. Where evidence gaps were identified early and addressed through design, testing, or clinical studies. Where PMCF was planned as part of the evidence strategy, not as an afterthought.

This is not about perfection. It is about demonstrating that you understand the clinical reality of your device and have evidence to support its safe and effective use.

That is what Class IIb requires. Anything less creates delays, deficiencies, and eventual rejection.

If you are starting a Class IIb project, the time to build your clinical strategy is now—before design lock, before verification testing, and certainly before your first submission.

Clinical evaluation for these devices is not a final documentation step. It is the framework that guides everything else.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.